Cialis (Tadalafil): History and Development

The Origins of PDE5 Research

The story of tadalafil begins with nitric oxide (NO) signaling. In 1992, Robert Furchgott, Louis Ignarro, and Ferid Murad received recognition for identifying NO as a vascular signaling molecule, work that would earn the Nobel Prize in Physiology or Medicine in 1998. NO activates guanylate cyclase, raising intracellular cyclic guanosine monophosphate (cGMP) levels, which relaxes smooth muscle in penile corpus cavernosum tissue. PDE5 degrades cGMP. Block PDE5, and cGMP accumulates longer after sexual stimulation, sustaining erections.

Pfizer's sildenafil (Viagra) reached the market in March 1998, proving the PDE5 mechanism worked clinically. But sildenafil had a 3-to-5-hour half-life and notable cross-reactivity with PDE6 (causing blue-tinted vision in some patients). These limitations created an opening. ICOS Corporation, a biotechnology firm based in Bothell, Washington, had been screening compound libraries for selective PDE5 inhibitors since the early 1990s. Their medicinal chemistry team, led by Andrew Bell and colleagues, identified a methylenedioxyphenyl-based scaffold that would become tadalafil.

ICOS, Glaxo, and the Eli Lilly Partnership

ICOS initially partnered with Glaxo Wellcome in 1994 to co-develop the PDE5 program. The collaboration screened over 1,000 compounds. Early candidate IC351 showed strong selectivity for PDE5 over PDE6 (roughly 700-fold in enzyme assays), which predicted fewer visual side effects compared to sildenafil's approximately 7-fold selectivity gap [1]. Glaxo Wellcome withdrew from the partnership in 1996, before Phase II trials began.

Eli Lilly stepped in. In 1998, Lilly and ICOS formed a 50/50 joint venture to develop and commercialize IC351. That compound was tadalafil. The partnership pooled Lilly's global regulatory infrastructure with ICOS's molecular pharmacology expertise. Phase I trials established that tadalafil's half-life was approximately 17.5 hours, several times longer than sildenafil or vardenafil (4 to 5 hours each). This pharmacokinetic profile hinted at a dosing flexibility no existing ED drug could match.

How Tadalafil Works: Mechanism of Action

Tadalafil inhibits PDE5, the enzyme responsible for breaking down cGMP in vascular smooth muscle. When a man is sexually aroused, nerve terminals and endothelial cells in the penis release nitric oxide. NO stimulates soluble guanylate cyclase, producing cGMP from GTP. Rising cGMP activates protein kinase G, which phosphorylates targets that reduce intracellular calcium, relax smooth muscle cells in the corpus cavernosum, and increase arterial blood flow into the penis. The result is an erection.

PDE5 normally hydrolyzes cGMP back to inactive 5'-GMP within minutes. Tadalafil binds the catalytic site of PDE5 and slows this degradation. The drug does not produce erections on its own. Sexual stimulation is required to initiate NO release. Tadalafil simply amplifies and prolongs the downstream cGMP signal [2].

What makes tadalafil structurally distinct from sildenafil and vardenafil is its methylenedioxyphenyl group. This chemical feature gives tadalafil greater selectivity for PDE5 over PDE6 and PDE1, reducing the incidence of color-vision disturbances and cardiovascular effects seen with less selective agents. Tadalafil also shows minimal PDE11 inhibition at therapeutic doses, though PDE11's physiological role remains under investigation.

The long half-life (17.5 hours, compared with 3 to 5 hours for sildenafil) results from tadalafil's slower hepatic clearance via CYP3A4. Peak plasma concentration occurs at roughly 2 hours post-dose, and clinically meaningful drug levels persist for up to 36 hours in many patients. This is why tadalafil earned the informal label "the weekend pill."

Key Clinical Trials

The Brock 2002 Study

The trial that established tadalafil's clinical profile was a 12-week, multicenter, randomized, double-blind, placebo-controlled study led by Gerald Brock and published in the Journal of Urology in 2002 [3]. The study enrolled 348 men with ED of at least three months' duration. Participants received placebo, tadalafil 10 mg, or tadalafil 20 mg on an as-needed basis.

Results were definitive. The 20 mg group reported successful intercourse attempts 75% of the time versus 32% for placebo. The 10 mg group achieved 67% success. Both doses produced statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain scores (P<0.001 for both vs. placebo). The study also tested efficacy at extended time points. At 24 and 36 hours post-dose, tadalafil 20 mg still produced significantly higher intercourse success rates than placebo. No other PDE5 inhibitor had demonstrated that duration of action [3].

Integrated Analyses and Long-Term Data

Pooled analyses of five Phase III studies (total N=1,112 on tadalafil) confirmed consistent efficacy across subgroups including men with diabetes, post-prostatectomy patients, and those with severe ED [4]. Long-term open-label extensions showed tadalafil maintained efficacy over two years of continuous use without dose escalation in most patients. Dropout rates due to adverse events were low (approximately 3.5%).

Common side effects included headache (14.5%), dyspepsia (12.3%), back pain (6.5%), and nasal congestion (4.2%). The back pain and myalgia seen with tadalafil (but not sildenafil) are thought to relate to PDE11 inhibition in skeletal muscle, though definitive evidence for this mechanism is limited.

FDA Approvals: A Timeline

The FDA approved tadalafil as Cialis for on-demand treatment of ED on November 21, 2003, at doses of 5 mg, 10 mg, and 20 mg [5]. The approval came five years after sildenafil and in the same year as vardenafil (Levitra, approved August 2003). Three PDE5 inhibitors were now on the market.

The next milestone was daily dosing. In January 2008, the FDA approved Cialis 2.5 mg and 5 mg for once-daily use in ED [6]. This was a category-first. No other PDE5 inhibitor had a half-life long enough to support continuous steady-state dosing. For men with frequent sexual activity (twice weekly or more), daily dosing eliminated the need to plan around pill timing.

Then came the BPH indication. In October 2011, the FDA approved Cialis 5 mg daily for benign prostatic hyperplasia, making tadalafil the first (and still only) PDE5 inhibitor approved for lower urinary tract symptoms [7]. The key trial demonstrated that tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 4.8 points versus 2.2 for placebo at 12 weeks, a clinically meaningful difference. This approval meant a single 5 mg daily tablet could treat both ED and BPH in the same patient.

Separately, in 2009 the FDA approved tadalafil at 40 mg daily under the brand name Adcirca for pulmonary arterial hypertension (PAH), based on the PHIRST trial (N=405), which showed improved 6-minute walk distance by 33 meters versus placebo.

The Economic Story: Blockbuster to Generic

Cialis became one of the highest-grossing pharmaceuticals in history. Global sales peaked at $2.79 billion in 2014, according to Eli Lilly's annual reports. In 2017, Cialis generated $2.3 billion in revenue, representing nearly 10% of Lilly's total sales that year.

Lilly acquired full ownership of the drug in 2007 by purchasing ICOS Corporation for $2.3 billion, ending the joint venture. The acquisition gave Lilly 100% of Cialis profits and full control over the daily-dosing regulatory strategy and the BPH indication filing.

The compound patent for tadalafil (US Patent 5,859,006) expired in November 2017. However, additional patents covering the daily-dose formulation extended market exclusivity until September 2018. Generic tadalafil entered the US market in late 2018. Within two years, generic competition had reduced the average cash price by roughly 95%. A 30-day supply of generic tadalafil 5 mg daily now costs between $10 and $40 at most US pharmacies, compared to brand Cialis prices that once exceeded $400 per month.

Tadalafil's Influence on Modern ED Therapy

The development of tadalafil changed prescribing patterns for erectile dysfunction. Before daily Cialis, ED treatment was purely episodic. A man took a pill, waited for it to work, and had a defined window. Tadalafil's pharmacokinetics introduced the concept of "readiness." Men on 5 mg daily reported improved spontaneity and relationship satisfaction in multiple quality-of-life substudies [8].

The dual ED/BPH indication also shifted urology practice. The American Urological Association now lists tadalafil 5 mg daily as a treatment option for men with concurrent LUTS and ED, noting that it addresses both conditions with a single medication. This is particularly relevant given that both conditions increase in prevalence after age 50 and share overlapping smooth-muscle and NO/cGMP pathology.

Dr. Arthur Burnett, professor of urology at Johns Hopkins and a member of the AUA's ED guideline panel, has stated: "Tadalafil's long half-life and dual indication changed how we think about PDE5 inhibitors. It moved the class from an event-driven intervention to a daily therapeutic."

A second expert perspective comes from the Endocrine Society's 2018 clinical practice guideline on testosterone therapy, which noted: "In men with ED and hypogonadism, PDE5 inhibitors, particularly tadalafil given its dual BPH benefit, should be considered as adjunctive therapy alongside testosterone replacement" [9].

Ongoing Research and Future Directions

Tadalafil continues to be studied beyond its approved indications. Active research areas include Raynaud phenomenon, where a 2019 Cochrane review found PDE5 inhibitors reduced attack frequency and severity, though most data came from sildenafil studies and tadalafil-specific evidence remains limited. Heart failure with preserved ejection fraction (HFpEF) is another area of investigation. The RELAX trial (N=216) tested sildenafil for HFpEF without benefit, but researchers have hypothesized that tadalafil's longer half-life and different tissue distribution may yield different results. A definitive tadalafil HFpEF trial has not been completed.

In the BPH space, researchers are evaluating combination therapy with tadalafil plus tamsulosin versus monotherapy with either agent. Early comparative studies suggest additive benefits for LUTS and sexual function, though large-scale randomized data are still emerging.

Generic availability has also expanded tadalafil's use in compounding pharmacies and telehealth platforms, where it is frequently prescribed alongside other medications for sexual health. The drug's well-characterized safety profile over two decades of post-marketing data supports this broader clinical use, provided appropriate screening for contraindications (nitrate therapy, severe hepatic impairment, and unstable cardiovascular disease) is maintained.

Tadalafil 5 mg daily remains the only oral medication simultaneously approved for ED and BPH, with over 20 years of continuous safety data since its first regulatory submission [10].